Question 1

How many clinical trials has Cancer Institute and Hospital, Chinese Academy of Medical Sciences sponsored?

Accepted Answer

ClinicalMetric currently tracks 16 clinical trials sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, of which 16 are actively recruiting participants. These trials cover conditions including Cervical Esophageal Cancer, Colorectal Cancer, Esophageal Neoplasm Metastatic. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

Question 2

What therapeutic areas does Cancer Institute and Hospital, Chinese Academy of Medical Sciences research focus on?

Accepted Answer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is a clinical research sponsor with 16 registered studies on ClinicalTrials.gov, of which 16 are actively recruiting participants. Research covers conditions including Cervical Esophageal Cancer, Colorectal Cancer, Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb.

The trial portfolio spans Phase 2, Phase 3, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Question 3

How do I participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trial?

Accepted Answer

To participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials with current recruitment status updated daily.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Frequently Asked Questions — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Clinical Trials by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Surgery or Chemoradiotherapy for Cervical Esophageal Cancer

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer

PLATFORM Study of Precision Medicine for Rare Tumors

Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)

Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Adaptive Radiotherapy for Genitourinary Cancers

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC